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Abstract
The pathogenesis of atherosclerosis involves dysfunctions of vascular endothelial cells and smooth muscle cells as well as
blood borne inflammatory cells such as monocyte-derived macrophages. In vitro experiments towards a better
understanding of these dysfunctions are typically performed in two-dimensional cell culture systems. However, these
models lack both the three-dimensional structure and the physiological pulsatile flow conditions of native arteries. We here
describe the development and initial characterization of a tissue engineered artery equivalent, which is composed of human
primary endothelial and smooth muscle cells and is exposed to flow in vitro. Histological analyses showed formation of a
dense tissue composed of a tight monolayer of endothelial cells supported by a basement membrane and multiple smooth
muscle cell layers. Both low (LDL) and high density lipoproteins (HDL) perfused through the artery equivalent were
recovered both within endothelial cells and in the sub-endothelial intima. After activation of the endothelium with either
tumour necrosis factor alpha (TNFa) or LDL, monocytes circulated through the model were found to adhere to the activated
endothelium and to transmigrate into the intima. In conclusion, the described tissue engineered human artery equivalent
model represents a significant step towards a relevant in vitro platform for the systematic assessment of pathogenic
processes in atherosclerosis independently of any systemic factors.
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Introduction
Atherosclerosis is responsible for a substantial global disease
load and remains a major cause of morbidity and mortality
worldwide. One of the first events in the pathogenesis of
atherosclerosis is the insudation of cholesterol-rich low density
lipoprotein (LDL) into the innermost intimal layer of the arterial
wall where they are bound by proteoglycans and eventually
modified [1]. In parallel and further enhanced by the retained
lipoproteins, the activated endothelium binds immune cells such as
monocytes, which subsequently transmigrate the endothelium.
Within the arterial intima the monocytes differentiate into
macrophages which upon receptor mediated uptake of LDL are
transformed into foam cells. They form the early ‘‘fatty streak’’
lesion [2]. The inflammatory reaction of macrophage foam cells
but also other immigrating immune cells induce the progression to
more complicated lesions and ultimately vulnerable plaques,
which upon rupture or erosion elicit the acute complications of
atherosclerosis such as acute coronary events. High density
lipoproteins (HDL) counteract several of these pro-atherogenic
activities by various mechanisms. The classical potentially anti-
atherogenic property is related to its ability to remove cholesterol
from the macrophage foam cells within the arterial wall and
mediate the transport to the liver for excretion into the bile [3]. To
do this HDL must also cross the endothelial barrier in order to get
access to the cholesterol-loaded macrophages [3].
In addition to various in vivo models, notably genetically
modified mice, [4] cell culture experiments have been valuable
tools to unravel the above summarized pathomechanisms of
atherosclerosis. However - so far - most of the in vitro experiments
are performed using single types of cells grown on regular static
plastic dishes. Importantly, these studies are associated with
significant limitations, as they do not account for the complexity of
the native artery environment with all the cell-cell and/or cell-
matrix interactions. To address these limitations, several labora-
tories developed co-culture models of endothelial cells and smooth
muscle cells [5–7]. However, also these studies were limited by the
unphysiological attachment of cells to plastic dishes or trans-well
membranes and co-culture times which were too short for the
development of typical vascular cell-extracellular matrix interac-
tions. In the attempt to address these limitations, Dorweiler et al.
developed a long-term co-culture setup on fibrin gels [8]. In this
model they demonstrated for the first time the feasibility to analyse
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in vitro the accumulation of LDL and immunocytes in a sub-
endothelial matrix [8,9]. However, also this static and non-
dynamic co-culture system is limited by the lack of both the
circular structure of arteries and the physiological vascular
hemodynamic situation characterized by flow and shear-stress.
In recent years, several laboratories fabricated tissue engineered
artery equivalents under pulsatile, native-like flow conditions for
the therapeutic and regenerative repair of congenital and acquired
malformations [10–13]. These bioengineered autologous cell-
based constructs were also successfully implanted into large animal
models and revealed native-like behaviour and development up to
240 weeks in vivo [14]. In the present study we used human
vascular cells to engineer a 3D artery model mimicking the
structural as well as functional characteristics of a native artery.
This native-analogous bioengineered artery model was used to
study initial events in atherosclerosis, namely the accumulation of
LDL and HDL in the intima as well as the binding and
transmigration of monocytes under dynamic pulsatile flow
conditions.
Methods
Isolation of Umbilical cord cells
Mature vascular cells were isolated from human umbilical cord
vessels. All experiments were performed under Zurich cantonal
ethical permission and written informed consent was obtained
from all patients [KEK-2009-95]. Human umbilical vein endo-
thelial cells (HUVECs) and human umbilical cord derived
myofibroblasts (UCMFBs) were isolated and characterized as
previously described [10,14]. In brief, HUVECs were isolated
using the collagenase instillation technique. For this, the umbilical
cord vessels were incubated in collagenase (2 mg/ml; Collagenase
A; Roche Diagnostics GmbH.) dissolved in serum-free medium
(EBMTM; LONZA Inc., Switzerland). After 20 min of incubation,
the cell suspension was centrifuged and isolated cells were
expanded in endothelial growth medium (EGMTM-2) (LONZA
Inc., Switzerland; supplemented with vascular endothelial growth
factor (VEGF), human recombinant insulin-like growth factor-1
(hrIGF-1), human epidermal growth factor (hEGF), gentamycin,
amphotericin-B, hydrocortisone, ascorbic acid, heparin, and 2%
fetal bovine serum (FBS)). For the isolation of UCMFBs the
remaining vessels were minced into small pieces (,2–3 mm) and
incubated without medium under the sterile laminar flow for 25–
30 min to ensure physical attachment of the minced pieces.
Subsequently, advanced Dulbecco’s Modified Eagle Medium
(DMEM) medium (Invitrogen Corp., USA; supplemented with
10% FBS; 0.05% Penicillin/Streptomycin, 0.02% Fungizone and
1% L-glutamine) was carefully added to the minced vessel pieces
and the adherent myofibroblastic cells were expanded up to
passage 6.
In vitro fabrication of tissue engineered vascular grafts
Biodegradable tubular scaffold matrices (length 4 cm and inner
diameter 0.6 cm) were fabricated as described previously[10].
Briefly, non-woven polyglycolic-acid meshes (PGA; Cellon,
Luxembourg) were dip-coated with poly-4-hydroxybutyrate
(P4HB; TEPHA Inc., USA) by dipping it into a 1.75% (w/w)
solution of P4HB/tetrahydrofuran solution (Sigma Aldrich).
Vascular shape was obtained by heat application and a welding
technique before external coating with 10% P4HB/tetrahydrofu-
ran solution. After sterilization with 70% ethanol (30 min) followed
by 3 washes with PBS or by ethylene oxide exposition, PGA-P4HB
composite scaffolds were pre-incubated in DMEM medium
overnight before cells seeding. UCMFBs (3–46106 cells/cm2)
were seeded in the inner surfaces of the vascular scaffold using
fibrin (Sigma Aldrich) as a cell carrier [15]. After a short static
incubation period (3 days), vascular constructs were exposed to
dynamic conditioning in a flow bioreactor system for 14 days. The
flow of nutrient medium (DMEM with 10% FBS; 0.05%
Penicillin/Streptomycin, 0.02% Fungizone, 1% L-glutamin and
1.5 mM L- ascorbic acid) was directed through their inner lumen
of the bioreactor circulation loop, exposing the seeded constructs
to an increasing flow over time (from 5 to 10 mL/min). Vascular
grafts were then endotheliazed with HUVECs (1.56106 cells/cm2)
and cultivated first in static condition for 5 days in EGMTM-2
medium with supplements as described above. After the static
phase, vascular grafts were placed back in the bioreactor for 14
additional days with increasing medium flow (from 3 to 10 mL/
min).
Isolation and labeling of LDL and HDL
Human LDL (1.006,d,1.063 kg/L) and HDL
(1.063,d,1.21 kg/L) were isolated from fresh normolipidemic
plasmas of blood donor by sequential gradient ultracentrifugation
[16]. The purity of the lipoprotein preparation was verified by
sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE) in order to assure no cross or albumin contamination.
Freshly isolated LDL or HDL was fluorescently labeled with atto-
633 (Invitrogen) following manufacturer instructions. Fluorescent
LDL (20 mg/ml in EGMTM-2 medium supplemented as described
previously) was injected in the circulatory loop of the bioreactor in
the absence or presence of a 40 folds excess (0.8 mg/ml) of non-
labeled LDL. After 2.5 or 24 hours vascular grafts were removed
and processed directly using confocal microscopy (CLSM SP5,
Leica) or frozen in embedding matrix (O.C.T., Biosystem) for
further analyses. Fluorescently labeled HDL (25 mg/ml in
EGMTM2 medium supplemented as described previously) was
injected into the circulatory loop of the bioreactor system or
injected into the medium adherently cultured cells. After 4 or
24 hours tissue engineered vascular grafts were removed and
further processed as described for LDL.
Isolation and labeling of monocytes
Monocytes were isolated from healthy donors by centrifugation
on a continuous density gradient (PercollTM; Amersham biosci-
ence, GE health care) as described previously [17]. Freshly isolated
monocytes were fluorescently labeled with 10 mM of SNARFH-1
carboxylic acid (Invitrogen) following the manufacturer’s instruc-
tions. 16106 monocytes per mL were injected into the circulation
loop of the bioreactor in EGMTM-2 medium supplemented as
described above but with 2% of FBS.
Histology and immunohistochemistry of tissue
engineered arteries
For histological characterization bioengineered grafts were fixed
in 4%-paraformaldehyde (PFA), dehydrated through a series of
graded ethanol, embedded in paraffin and sectioned at 7 mm
thickness. The sections were deparaffinized, rehydrated through a
graded ethanol series. The tissue sections were stained using
haematoxylin & eosin, haematoxylin & sudan and Masson-
trichrome. Immunohistochemistry analyses were performed with
antibodies specific for CD31 (clone JC/70A, DakoCytomation,
Glostrup, Denmark), a-smooth muscle actin (clone 1A4, Sigma)
and collagen IV (Quartett, Germany) using the Vantana
Benchmark automated staining system (Ventana Medicals Sys-
tems, Tucso,AZ) as previously described [10].
Engineered Artery to Study Atherosclerosis InVitro
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Biochemical extracellular matrix analysis
Representative tissue samples were lyophilized and analyzed by
biochemical assays for total DNA content as an indicator for cell
number, hydroxyproline (HYP) content as an indicator for
collagen, as well as glycosaminoglycans (GAG) content. For
measuring the DNA amount, the Hoechst dye method [18] was
used with a standard curve prepared from calf thymus DNA
(Sigma Chemical Co., USA). The GAG content was determined
using a modified version of the protocol described by Farndale et al.
[19] and a standard curve prepared from chondroitin sulphate
(Sigma Chemical Co., USA). HYP was determined using a
modified version of the protocol provided by Huszar et al. [20].
Native control tissues from human aorta were included and all
values are presented relative to these native values (% of native).
Confocal microscopy
Bioengineered grafts were first washed twice in PBS and then
fixed in 3.75% of PFA for 30 minutes at room temperature.
Following a second series of PBS washing phases (3x), grafts were
mounted in 0.1 M Tris-HCL, pH 9.5, and glycerol (3:7)
containing 50 mg/ml of n-propyl gallats as anti-fading reagent
[21] and 1 ng/ml of 4’,6-diamidino-2-phenylindole (DAPI) to
visualize the nuclei. Analyses of the engineered graft samples were
performed on an inverted confocal microscopy.
Preparation of the cryopreserve sections
Bioengineered grafts were first washed twice in PBS and then
cryopreserved in embedding matrix (O.C.T.). The grafts were
further processed on cryotome generating cuts with 12 mm
thickness. The cuts were stored at –80uC until further processing.
Cuts were rehydrated in PBS for 3610 minutes before fixing in
3.75% of PFA for 20 minutes at room temperature. After three
PBS washes cuts were blocked for 30 minutes in 5% donkey serum
in PBS. For immunofluorescence staining, the cuts were incubated
overnight at 4 uC with specific antibodies against ZO1 (33-9100,
Invitrogen), ABCG1 (HG5, Santa Cruz), SR-BI (NB 400-101 E4,
Novus) or EL (NB 400-111, Novus). After three additional PBS
washes cuts were incubated for 45 minutes at room temperature
with secondary antibodies (Dako) followed by three additional
washes with PBS and finally mounted in antifade solution
containing DAPI (Invitrogen). The expression of ABCG1, SR-BI
and EL were compared to a native radial artery frozen in
embedding matrix (O.C.T.) and cut as describe above. Analyses of
the cuts were performed on an inverted microscope (Zeiss).
Endothelium integrity
To analyse the endothelial integrity Evan’s blue (Sigma Aldrich)
was injected at a final concentration of 0.5% in the circulation
loop of the bioreactor for 10 minutes followed by PBS washing
phase for 10 minutes. Grafts were cut open and analysed
macroscopically with photo documentation.
Nitric oxide measurement
Nitric oxide synthesis was measured as described previously
[22]. In brief, following PBS wash 5 mm vessel rings were
incubated in assay buffer (50 mM Tris-Cl, pH7.4, 0.25 mM
EDTA, 0.3 mM CaCl2, 0.25 mM DTT, 25 mM L-arginine,
1 mM NADP, 100 nM calmodulin, 10 mM tetrahydrobiopterin
and 1.25 mCi L-3H-arginine; PerkinElmer) in the presence of
10 nM acetylcholine (Ach), 0.5 mg/ml HDL or 1 mM L-NG-
nitroarginine methyl ester (L-NAME). After 30 minutes at 37uC,
the reaction was stopped by adding 1 ml of ice cold Hepes buffer
(50 nM HEPES, 5 mM EDTA, pH 5.5). Tissue was homogenized
using a tissue homogenizer (Precellys 24, Bertin Technologies) and
the supernatant was load onto ion exchange column (Dowex, 50
WX8-20, Sigma) previously equilibrated with stop buffer to
separate L-3H-citruline from L-3H-arginine. Scintillation mix
(Ultimate Gold, PerkinElmer) was added to the supernatant and
counted using b-counter (Betamatic, Kontron).
Statistic analysis
Statistical comparisons between different groups were per-
formed using a ANOVA. The data has been obtained from at least
2 different experiments and were graphically represented as mean
6 standard deviation of the mean (SEM). P-values of,0.05 were
considered statistically significant. All statistical anaylses were
performed using GraphPad Prism-5 software.
Results
Structure and characteristics of engineering arteries
For the assessment on the structural level, the engineered artery
equivalents were analysed macroscopically and microscopically.
Macroscopically the tube-like scaffolds had dimensions of 4 cm
length and about 0.6 cm diameter before seeding. After the in
vitro culture for about 5 weeks the scaffold was densely covered by
cells and demonstrated a patent lumen (Fig. 1). Some of the grafts
(15%) showed a central decrease of the luminal diameter. These
grafts were excluded from any further analyses.
Microscopy analyses with Haematoxylin-Sudan and Haema-
toxylin-Eosin staining demonstrated the formation of a dense and
homogenous tissue on the luminal side of the grafts and a loser
tissue formation in contact with the degraded scaffold on the outer
surface (Fig. 2 A-B). The tissue was composed of cells and
extracellular matrix as demonstrated by the presence of collagen in
Masson’s trichrome staining (Fig. 2 C). Immunohistochemistry
staining showed the presence of a-smooth muscle actin positive
cells in the inner layer of the vessel and CD31 positive cells
forming a monolayer on the luminal side (Fig. 2 D-E). Moreover,
the presence of a basement membrane underneath the endothelial
cells was demonstrated by the presence of collagen IV positive
layer (Fig. 2 F).
Figure 1. Bioreactor and macrostructure of the engineered
artery equivalent. A) Schematic view of the bioreactor set up. B)
Macroscopic picture of the bioengineered artery demonstrated the
presence of an open lumen after 5 weeks in culture as well as the
formation of tissue on the luminal side of the graft. Bar represents 1 cm.
doi:10.1371/journal.pone.0079821.g001
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The extracellular matrix composition of the graft was further
examined with biochemical analyses of the presence of DNA,
hydroxylproline (Hyp) or glycosaminoglycans (GAG) and the
results were compared with the data obtained for a native human
aorta. The GAG composition of the grafts was similar to the values
observed in native tissues, 103 6 23%. Interestingly the DNA and
Hyp values represented only 39.5 6 10% and 40 6 5%,
respectively of the native tissue values (see Fig. 3). In summary,
these results demonstrated that the engineered artery equivalents
mimicked the cellular structures as well as extracellular matrix
composition of a native artery.
Assessment of endothelial integrity and functionality
Next, the integrity of the endothelium was analysed using
Evan’s blue staining. As expected before endothelialisation, the
Evan’s blue dye was penetrating into the tissue and colouring
evenly the bioengineered graft. (Fig. 4 A). One week after the
seeding of endothelial cells, the subendothelial was less intensively
stained with Evan’s Blue, indicating the beginning but not
complete endothelialisation (data not shown). Two weeks after
endothelial cell seeding, the tissue was not coloured by Evan’s blue
any more indicating the presence of a tight endothelium (Fig. 4 B).
To confirm the presence of tight junctions between the endothelial
cells cryopreserved tissue was stained for tight junction protein 1
(ZO-1). The presence of ZO-1 expression on the luminal side of
the graft was demonstrated two weeks after endothelial cell seeding
(Fig. 4 C and D). To further characterize endothelial properties,
we measured nitric oxide (NO) production by the grafts. After
incubating two weeks old endotheliazed vessels with 0.5 mg/ml
HDL (p,0.01) or 10 nM acetylcholine (p,0.001) we measured a
significant increase of L-3H-arginine to L-3H-citruline and NO
conversion. In the presence of the specific NO synthase inhibitor
L-NG-nitroarginine methyl ester (L-NAME), the conversion was
significantly reduced (p,0.05) indicating NO synthesis by
endothelial cells in the grafts after both HDL and Ach stimulation
(Fig 4 E). Taken together these data suggest that the endothelium
of the engineered artery equivalent formed a functional barrier
isolating the subendothelial tissue from the luminal fluid as shown
with the Evan’s blue assay.
Low-density lipoprotein insudation and accumulation in
the tissue
The insudation and accumulation of LDL into the vasculature
represent early events in atherosclerosis development. To inves-
Figure 2. Histological structure of an engineered artery equivalent. A) Haematoxylin-Sudan staining demonstrated the formation of tissue in
and on the surface of a PGA/P4HB scaffold as well as the scaffold’s partial degradation. B) H&E staining revealed dense tissue formation composed of
cells and extracellular matrix. C) The secretion of collagen was observed after Masson’s trichrome staining. The expression of a-smooth muscle actin
(a-SMA) (D) confirmed the smooth muscle phenotype of the cells in the inner layer. Collagen IV positive staining (E) demonstrated the secretion of
basement membrane and CD31 positive staining (F) confirmed the presence of an endothelial cell monolayer on the luminal side of the
bioengineered artery equivalent. Bars represent 100 mm.
doi:10.1371/journal.pone.0079821.g002
Figure 3. Quantification of extracellular matrix composition
and cell number. Total cell numbers, represented as DNA and total
collagen secretion of collagen, represented as hydroxyproline (HYP)
represented < 50% of the native human aorta. The glycosaminoglycan
(GAG) content was similar to native aorta.
doi:10.1371/journal.pone.0079821.g003
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tigate whether our engineered artery equivalent is suitable to
mimic this step in atherogenesis, fluorescently labelled LDL was
injected into the circulation loop of the dynamic graft culture. The
tissue was collected after 2,5 and 24 hours and analysed by
confocal imaging after fixation or cryopreserved for immunoflu-
orescence. Confocal images were taken from the lumen of the graft
and then – by changing the z-plane – by focusing deeper into the
tissue. LDL was clearly localized intracellular in cytosolic vesicles
within the luminal cell layer after 24 hours (Fig. 5 A). To verify the
specific uptake of LDL, the engineered grafts were incubated with
fluorescently labelled LDL in the presence of a 40 fold excess of
non-labelled LDL, the signal was dramatically reduced (Fig. 5 B).
This observation confirms the specificity of the LDL up-take into
the engineered artery equivalent. Cryo-sections of the graft
isolated at 2.5 and 24 hours demonstrated a time dependent
uptake of LDL by the tissue. Indeed the signal emitted by the
fluorescent LDL increased over time (Fig. 5 C & F). After
2.5 hours, LDL was mainly localized within the endothelial cell
layer with minimal signal in the sub-endothelial space (white arrow
Figure 5 C-E). After 24 hours LDL was still localized in the
endothelial cell layer but the sub-endothelial tissue revealed an
increase of fluorescence (white arrow Fig. 5 F). Indeed in the sub-
endothelial tissue LDL was found to accumulate either in spots
(Fig. 5 G) or diffuse areas (Fig. 5 H). These results indicate the
possibility to study trans-endothelial transport and sub-endothelial
accumulation of LDL in our model.
Monocyte binding and insudation in engineering artery
To investigate if our model is suitable to analyse the attachment
and trans-endothelium migration of monocytes into the interstitial
vascular tissue, labelled monocytes were injected into the
bioreactor circulation loop and tracked by confocal imaging and
cryo-section analysis. The isolated monocytes were CD14 positive
and after in vitro culture they express CD68 (data not shown).
Monocytes were labelled with SNARF-1 dye after the isolation
and the capacity of the labelled monocytes to bind to activated
endothelial cells was verified in conventional cell culture (data not
shown). The labelled monocytes were injected into the circulating
medium of the graft in the absence or presence of 3 hours pre-
treatment with TNFa. After 24 hours incubation, the attachment
of the monocytes on the arterial graft was monitored by confocal
imaging and demonstrated an increased number of monocytes
adhering to the graft after TNFa pre-incubation (white arrows;
Fig. 6 A-B). Moreover after 24 hours pre-incubation of the graft
with LDL, the monocytes attached to the endothelium to a similar
extent as compared with the TNFa pre-stimulation (Fig. 6 C).
Interestingly, if the monocytes were added simultaneously with the
LDL no increase of monocyte adhesion could be observed
compared to the non-stimulated grafts (data not shown). In
addition, the attachment of the monocytes to the scaffold alone
was investigated and demonstrated no adhesion. To quantify
monocyte adhesion, monocytes having remained in the circulation
after 24 hours were counted and compared to the monocyte
number of the control group (monocyte perfusion of scaffold only).
The numbers of monocytes in the circulation after TNFa and
LDL pre-stimulation 17.563.0% and 20.863.5% respectively
were not statically different (p = 0.226). However, they were
significantly lower compared to the not stimulated engineered
arteries (33,762,8%), p,0.0001 for TNFa and p,0.0001 for
LDL. These results indicate that significantly more monocytes
were bound under stimulated conditions. Microscopy of the cryo-
sectioned tissue after LDL pre-incubation demonstrated the
presence of monocytes adhering to the endothelial surface and
migrating into the tissue (Fig. 6 E & G). In addition, monocytes
were also identified in the tissue after LDL pre-treatment (Fig. 6 F
& H-I). These results indicate that our engineered artery
equivalent represents a suitable tool to study the attachment and
transmigration of monocytes into the artery, which represents a
key process in the development of atherosclerosis in vivo.
High density lipoprotein insudation in engineered artery
HDL is an important key player in the development of
atherosclerosis development. Indeed HDL is believed to have a
major anti-atherosclerotic potential by removing the excess
cholesterol out of the macrophages in the arterial wall. In this
context, the trans-endothelial transport of HDL remains a
Figure 4. Integrity and functionality of endothelial cells in the
engineered artery. The endothelial integrity was analysed using
Evan’s blue staining (0.5% for 10 minutes). In the absence of endothelial
cell (A) the tissue appeared evenly stained in blue. Two weeks after
endothelialization (B) the endothelial barrier retained the absorption of
Evan’s blue and tissue appeared non-coloured. The integrity of the
endothelium was further analysed by microscopy of cryosections for
the expression of the tight junction protein (ZO)-1 (red) by endothelial
cells (nuclei: blue). (C & D). Nitric oxide was measured using L-3H-
arginine as the substrate and in presence of 10 nM acetylcholine (Ach)
or 0.5 mg/ml HDL as the stimulator or 1 mM L-NAME as the inhibitor of
endothelial nitric oxide synthase (eNOS). After 30 minutes L-3H-citruline
was separated from L-3H-arginine by ion exchange column. Bar
represents 100 (C) and 25 mm (D) and L: Lumen. *** p,0.001,
** p,0.01 and * p,0.05
doi:10.1371/journal.pone.0079821.g004
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potentially limiting step to be elucidated [23]. The ATP binding
cassette (ABC) G1, the scavenger receptor (SR)-BI and endothelial
lipase (EL) were demonstrated to participate in the trans-
endothelial transport of HDL in cell culture [24]. In order to
analyse HDL transport across the endothelium the expression of
the known HDL binding proteins were investigated by immuno-
fluorescence stainings. Specific stainings with antibodies against
ABCG1, SR-BI and EL demonstrated the high expression of those
markers by both HUVECs and HUMFBs in the engineered artery
equivalent in a comparable pattern as in a native artery (Fig. 7).
To further investigate whether our model is suitable to analyse the
transport of HDL through endothelial cells, we incubated the
bioengineered graft with fluorescently labelled HDL. Similar as
described for LDL, cryosection of the harvested engineered
arteries demonstrated the presence of HDL in the endothelial
cells as well as the accumulation of HDL in the sub-endothelial
space (Fig. 8A). In addition, the distribution of HDL was analysed
by confocal microscopy. Interestingly, HDLs were localised either
in intracellular vesicles or as extracellular diffused material if
incubated with engineered arteries under flow conditions (Fig. 8B).
Figure 5. Insudation of LDL into the engineered artery. The insudation of LDL into the tissue (blue: nuclei) was analysed by confocal
microscopy after incubation with 20 mg/ml of fluorescent LDL (white) for 24 hours and demonstrated the vesicular localization on the upper cell layer
(A). The specificity of the signal was assessed by competition with 40-fold excess of non-labelled LDL (B). LDL localization in the tissue was further
analysed by microscopy of tissue cryosections and demonstrated the time-dependent uptake and the sub-endothelial localization of the LDL (C:
2.5 hours and F: 24 hours). Zoom in of interesting regions shown with the arrows are presented in D and E for 2.5 hours and F and G for 24 hours.
Bars represent 200 mm (A-C,F) and 20 mm (D-E, G-H) and L: Lumen.
doi:10.1371/journal.pone.0079821.g005
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However, under static non-flow conditions labelled HDL was
recovered in intracellular vesicles only (Fig. 8 C & D). These
differences between static (non-flow) cell culture conditions and the
flow conditions of our engineered arteries demonstrates the
potential of the proposed model to study HDL transport under
in vitro in conditions which are closer to the native situation.
Discussion
Given its substantial negative socioeconomic impact, athero-
sclerosis has been intensively studied in the last decades. In
particular, many efforts have been undertaken to develop an
adequate ex vivo model for the biofunctional large-scale assess-
ment of ethiopathogenetic phenomena in vitro. The development
of endothelial and smooth muscle cell co-culture systems for the
assessment of monocyte transmigration and accumulation in the
artery intima, representing a key step in the pathogenesis of
Figure 6. Endothelial monocyte adhesion and transmigration migration in the engineered artery. After pre-treatment in the absence (A,
D) or the presence of 3 hours TNFa (10 ng/ml) (B, D) or 24 hours LDL (20 mg/ml) (C-I) 16106 fluorescently labelled monocytes (white) per ml were
injected into the circulation loop and circulated for 24 hours. Tissues were analyzed by confocal microscopy and after cryosectionning. In addition,
monocytes remaining in the circulation were counted. More monocytes (white arrows) adhered after pre-treatment with TNFa (B) or LDL (C)
compared to the not stimulated (A). Less monocyte remained into the circulation after TNFa or LDL pre-treatment compared to the absence of
stimuli (D). Monocytes adhesion and migration in the tissue was further analyzed by microscopy of cryosections after LDL pre-treatment. Microscopic
observations demonstrated adhesion and migration of monocytes through the endothelium (dash line) (E, G) and accumulation of monocytes into
the tissue (F, H-I). Bars represent 200 mm (A-C, E-F) and 20 mm (G-I).
doi:10.1371/journal.pone.0079821.g006
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atherosclerosis, was already proposed in the early 1990’s [5,6].
However, as already emphasized by Dorweiler et al., these co-
culture systems allow neither for long term in vitro culture nor
histology and extracellular matrix analyses [8]. Their own co-
culture system on a fibrin gel allowed longer culture times for up to
6 weeks and hence represented a major step forwards the in vitro
modelling of atherosclerosis[8,9]. Nevertheless, in spite of this
improvement, also this approach was missing a major physiologic
aspect evident in the biology of native arteries - that is the presence
of (pulsatile) blood flow in a lumen. This seems most important
because atherosclerotic lesions prevail at the site of altered blood
flow as first reported by Caro et al. [25].
Therefore, the present study addressed the question whether
bioengineered artery equivalents - as previously developed as
therapeutic replacements for patients with structural cardiovascu-
lar disease [10–13]- are suitable for modelling essential pathogenic
phenomena of atherosclerosis in vitro. In particular, the pulsatile
native-like flow environment could represent a major advantage in
this regard when compared to previous studies using static cell
culture environments.
As previously shown, histological analyses of the bioengineered
grafts demonstrated a structure similar to the layered microstruc-
ture of the native artery [10,14,26]. These constructs were equally
covered with a multi-layer of a-smooth muscle actin positive cells
indicating the development of a media-like layer. The presence of
secreted extracellular matrix components, such as collagen and
glycosaminglycans demonstrated the in situ functionality of
smooth muscle cells in the tissue. However, the biochemical
DNA and the collagen quantification, revealed lower values than
found in the native artery. This phenomenon has been previously
described and supposed to be due to the relatively short in vitro
culture periods [10]. This is further supported by the experiments
in large animal models, where tissue engineered arteries were
exposed to longer in vitro and in vivo conditioning and eventually
showed higher extracellular matrix values [14]. The positive layer
of collagen IV suggested the presence of a basement membrane,
that is secreted by the endothelial cells and separates them from
the subendothelial space [27]. In addition, the luminal side was
covered with a monolayer of endothelial cells on top of the
basement membrane. Another major function of the endothelium
is the formation of a tight barrier between the blood and the
interstitial vascular tissue. In our engineered grafts, the integrity of
the endothelial layer was confirmed by its impermeability for
Evan’s blue stain as well as by the expression of the ZO-1.
Endothelial functionalty was confirmed by NO production and
monocyte adhesion after TNFa stimulation.
The microscopic demonstration of labelled LDL in intracellular
vesicles and the sub-endothelial space indicate the uptake and
resecretion of LDL. According to the response-to retention model,
the accumulation of LDL in the sub-endothelial space is a crucial
step in the formation of atherosclerotic lesions [28]. Besides the
accumulation of LDL, inflammatory processes play an indispens-
able role in the pathogenesis of atherosclerosis, for example by
endothelial cell activation and subsequent monocyte adhesion
[29]. Therefore, we applied TNFa to analyse monocyte adhesion
to the endothelium. The observed significant increase of monocyte
adhesion after stimulation with either TNFa or LDL hence
provides another indication that our model is feasible to study
pathogenic events.
The trans-endothelial transport of HDL in the arterial wall for
removal of cholesterol accumulation is a key step in the reverse
cholesterol transport [3]. In addition, apoA-I - the major
apolipoprotein of HDL - was found to be present in atherosclerotic
plaque by recent investigations [30]. In agreement with these
histological descriptions and our previous findings of trans-
endothelial HDL transport in transwell cell culture we found
immunofluosecently labelled HDL both in endothelial cells and
the sub-endothelial space of our 3D model.
In conclusion, we demonstrate for the first time the feasibility to
engineer a dynamic 3D human artery equivalent for the
investigation of fundamental processes involved in the develop-
ment of atherosclerosis in vitro. In the contrary to previous
investigations, this model combines the engineering of a native-like
multilayer 3D architecture of the vascular wall with a lumen and
the applicability of native-analogous pulsatile flow profiles.
Thereby, this unique model mimics the native-like vascular
environment and may therefore also allow for more representative
in vitro investigations with higher predictive value for human
pathologies in vivo. In addition, this model may also allow for
large scale in vitro drug screening experiments – in particular by
enabling the specific modulation of several parameters (i.e. flow,
pressure, LDL, HDL, type of immune cells, etc). Thus, this model
may ultimately help to significantly reduce the necessity of animal
experiments in the field of atherosclerosis research. We therefore
believe that our model represents an important step towards the
development of a native-like large-scale atherosclerosis in vitro
disease model, which may help to improve our understanding of
this important pathology.
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